TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03770624
Drug: QL-007 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: QL-007 will be administered orally daily over the 28 days under fasted state.
Study: NCT02488889
Drug: placebo beverage (for alcohol)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01729871
Drug: uninterrupted vitamin K antagonist (VKA)
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
Study: NCT00718692
Drug: Sym001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each cohort will receive one single dose of Sym001 according the assigned dose level.
Study: NCT03176563
Drug: Placebo to Arctuvan
Approvals — FDA: no, EMA: no, PMDA: no
Description: application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
Study: NCT00857857
Drug: GW870086X
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational product
Study: NCT00160381
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral Daily for 12 months
Study: NCT00857857
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo control
Study: NCT03180125
Drug: Corticosteroid and 1%lidocain
Approvals — FDA: no, EMA: no, PMDA: no
Description: injection in the carpal tunnel
Study: NCT03530280
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: The preoperative placebo oral tablet and the postoperative sham block will perform.
Study: NCT03977493
Drug: Placebo - Concentrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: One injection in each muscle.
Study: NCT00050947
Drug: oxcarbazepine
Normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03222401
Drug: 1 mg/kg single infusion of F598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg single infusion of F598
Study: NCT03222401
Drug: 3 mg/kg single infusion of F598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg single infusion of F598
Study: NCT03222401
Drug: 10 mg/kg single infusion of F598
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg single infusion of F598
Study: NCT01279681
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01279681
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01279681
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00741442
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo.
Study: NCT00338923
Drug: HO/03/03
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03217994
Drug: gel HP
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Description: gel of hygrogen peroxide for teeth bleaching
Study: NCT01043991
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05342272
Drug: Betaine taurine PVP gel
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: At the beginning of the trial (t0) each patient received a print-out summarizing the instructions for use of the products: they were instructed to apply during a 28 days treatment period 1 to 2 cm of GUM Hydral® gel to gums, oral mucosa membrane and tongue, repeating as many times as necessary, and to brush their teeth with GUM® Technique® Pro soft compact toothbrush (Sunstar Europe S.A., Etoy, Switzerland) using GUM® Hydral® Toothpaste (Sunstar Europe S.A., Etoy, Switzerland) at least twice a day. The first application was done by the participants themselves under the supervision of the same operator that provided them both oral and written usage instructions. They had to refrain from using any other commercial mouthrinse, toothpaste or saliva supplements during the trial.
Study: NCT00523120
Drug: diclofenac sodium
Normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical solution used in ear 5 drops 8 3/day
Study: NCT01286740
Drug: FTC/RPV/TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
Study: NCT00523120
Drug: dexotc
Approvals — FDA: no, EMA: no, PMDA: no
Description: aural drops
Study: NCT00965575
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects. Taken 30 minutes prior to bedtime for four weeks.
Study: NCT00965575
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo. Taken 30 minutes prior to bedtime for four weeks.
Study: NCT01732770
Drug: Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid 5 mg administered by intravenous infusion once a year
Study: NCT01732770
Drug: Placebo to Zoledronic Acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Administered by intravenous infusion once a year
Study: NCT01096693
Drug: Urocortin 2, Urocortin 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release \[2, 4 and 8 pmol/min\]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.~Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3.
Study: NCT01096693
Drug: Saline placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.~Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1.
Study: NCT01862302
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
Study: NCT00666224
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
Study: NCT04685265
Drug: anle138b
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule containing excipient and anle138b
Study: NCT04685265
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo capsule containing excipient
Study: NCT01598909
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Application of Arnica ointment, twice a day, for the period of one week.
Study: NCT03956212
Drug: Doxycycline 7 days
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 7 days
Study: NCT03956212
Drug: Doxycycline 14 days
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patient will be treated with doxycycline orally, 100 mg, bid, 14 days
Study: NCT00547976
Drug: [C-11]PBR28
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02593669
Drug: Viscoelastic materials
Approvals — FDA: no, EMA: no, PMDA: no
Description: viscoelastic materials are used to protect corneal endothelial cells.
Study: NCT03547999
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control arm (Arm A) and experimental arm (Arm B) will receive mFOLFOX6 every 2 weeks for 4 cycles. Once patients in the post-operative period are deemed ready to begin therapy, patients in the control arm will then undergo another 8 cycles of mFOLFOX6.
Study: NCT00684970
Drug: Hamsa-1™ TL-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily Hamsa-1™ TL-118
Study: NCT02780362
Drug: Prodactariv
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 60 mg Daclatasvir
Study: NCT02780362
Drug: Clatazev
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet contains 60 mg Daclatasvir
Study: NCT01117441
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT01944735
Drug: CTX-4430
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
Study: NCT02161991
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
Study: NCT01117441
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT01117441
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: see detailed protocol description
Study: NCT01944735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
Study: NCT01183949
Drug: AT7519M
Approvals — FDA: no, EMA: no, PMDA: no
Description: Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m\^2/dose and will be increased to 27mg/m\^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.~Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.~Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose.
Study: NCT03255551
Drug: Amosartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
Study: NCT01117441
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: see detailed protocol description
Study: NCT00705367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion, Intravenous, single dose, Day 1
Study: NCT00385138
Drug: Placebo bolus & placebo infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo bolus (30 mcg/kg) \& placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
Study: NCT00385138
Drug: Placebo capsules - end of PCI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
Study: NCT00385138
Drug: Placebo capsules - end of infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
Study: NCT00491582
Drug: Growth hormone replacement therapy in growth hormone deficient patients only.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
Study: NCT00826111
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
Study: NCT02805725
Drug: Phase 1: Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
Study: NCT01062945
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching administration of a placebo pill.
Study: NCT01610336
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Phase Ib, INC280 was taken at escalating doses. During Phase II part, INC280 was taken at recommended Phase II dose.
Study: NCT00928564
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5ml of saline at each block site.
Study: NCT00741013
Drug: placebo pill and placebo IV
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Study: NCT00741013
Drug: Lovastatin pill and placebo IV
Normalized name: lovastatin Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS~Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Study: NCT00462865
Drug: Gemcitabine and Capecitabine and Avastin
Normalized name: Avastin
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
Study: NCT00730080
Drug: Sapropterin (Kuvan)
Normalized name: sapropterin Oral Tablet [Kuvan]
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
Study: NCT01496469
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
Study: NCT02002741
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
Study: NCT00863863
Drug: Grifulvin V® 125 mg/5 mL Suspension, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
Study: NCT02328287
Drug: ALLOB®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
Study: NCT02544919
Drug: SMOF lipid (SMOFLIPID) pre treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Arm
Study: NCT02253953
Drug: BILR 355 BS, D1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D2
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D3
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D4
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D5
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D6
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D7
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D8
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: BILR 355 BS, D10
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02253953
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02775448
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03833063
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: glabellar injections with sodium chloride
Study: NCT02312050
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00315003
Drug: Telithromycin
Normalized name: Telithromycin
DrugBank: Telithromycin (DB00976)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00315003
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00438321
Drug: Testosterone gel
Normalized name: Androgel 1.62% Metered Dose Pump Testosterone Gel
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01212250
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
Study: NCT01402024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient on control group with weight category of 15-40 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and~The patient on control group with weight category of 41-65 kg will receive:~D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule).
Study: NCT03464019
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.
Study: NCT00767806
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo once daily orally for 12 weeks
Study: NCT02733471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01626092
Drug: Campath-1H
Approvals — FDA: no, EMA: no, PMDA: no
Description: A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
Study: NCT02141542
Drug: MEDI3617
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01130064
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: every 3 weeks via intravenous infusion
Study: NCT03113253
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride to mimic tranexamic acid
Study: NCT03260595
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle
Study: NCT01376349
Drug: prasterone
Normalized name: Prasterone
DrugBank: Prasterone sulfate (DB05804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Applied vaginally
Study: NCT02630511
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consists of inhaling humidified air
Study: NCT00668603
Drug: 17-b-estradiol
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg oral daily for 6 months
Study: NCT00059839
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00059839
Drug: mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given by mouth
Study: NCT00059839
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV and intrathecally
Study: NCT01835197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
Study: NCT01835197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
Study: NCT01835197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
Study: NCT01835197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
Study: NCT01835197
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
Study: NCT00668603
Drug: 17-b-estradiol + medroxyprogeterone acetate
Normalized name: 17β-estradiol
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2mg E2 + 5mg MPA daily for 6 months
Study: NCT00668603
Drug: 17-b-estradiol hemihydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg skin gel daily for 6 months
Study: NCT00668603
Drug: placebo pill + gel
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo daily for 6 months
Study: NCT00818389
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: an inactive substance
Study: NCT03150316
Drug: Treat Regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1\~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
Study: NCT00165633
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo capsule, orally, three times a day, after meals.
Study: NCT00312325
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01336413
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as active comparator, except placebo dispensed.
Study: NCT02287376
Drug: Diclofenac Potassium for Oral Solution
Normalized name: Diclofenac Potassium for Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: NSAID